Prescrire International

  • Home
  • Prescrire International

Prescrire International Prescrire is a non-profit continuing education organisation, committed to better patient care.
(1)

Receive the free, monthly Newsletter from the editors of Prescrire International, a critical eye on new drugs authorised...
20/09/2024

Receive the free, monthly Newsletter from the editors of Prescrire International, a critical eye on new drugs authorised in Europe. Sign up here ➡ https://bit.ly/3uh2TBL?action=PIRSEPT

The pharmaceutical company Orexigen Therapeutics has failed to fulfil its obligation to conduct a post-authorisation tri...
19/09/2024

The pharmaceutical company Orexigen Therapeutics has failed to fulfil its obligation to conduct a post-authorisation trial to assess the long-term cardiovascular adverse effects of the fixed-dose combination of bupropion + naltrexone (Mysimba°), which is authorised in the European Union for use in patients with obesity or who are overweight. Now, 9 years after its authorisation, the European Commission has asked the European Medicines Agency to review its harm-benefit balance ➡ https://english.prescrire.org/en/81/168/68204/0/NewsDetails.aspx?action=PIRSEPT

For patients with relapsed or refractory multiple myeloma, various combinations of antineoplastic drugs extend survival....
06/09/2024

For patients with relapsed or refractory multiple myeloma, various combinations of antineoplastic drugs extend survival. Selinexor, an exportin-1 inhibitor, has been authorised in the European Union for use in multiple myeloma: in combination with bortezomib and dexamethasone after at least one line of treatment; and in combination with dexamethasone after at least four lines of treatment ➡ https://vu.fr/BmvIc

🔎 In the september issue of Prescrire International:- Selinexor in multiple myeloma: not acceptable- In-utero exposure t...
03/09/2024

🔎 In the september issue of Prescrire International:
- Selinexor in multiple myeloma: not acceptable
- In-utero exposure to corticosteroids: increased risk of infections
- Prescrire's annual review of drug packaging
This month's contents ➡ https://vu.fr/ajWB?action=PIRSEPT

Eye drops containing netarsudil, alone or combined with latanoprost, have been authorised in the European Union to lower...
08/08/2024

Eye drops containing netarsudil, alone or combined with latanoprost, have been authorised in the European Union to lower intraocular pressure in adults with chronic open-angle glaucoma or ocular hypertension. Netarsudil exposes patients to a higher risk of adverse effects than the first-choice ocular antihypertensive drugs, timolol or latanoprost, while offering no demonstrated gain in efficacy ➡ https://vu.fr/kGyhu?action=PIRSJUL

Prescrire has contributed to a public consultation on the proposed revision of the rules governing variations to marketi...
26/07/2024

Prescrire has contributed to a public consultation on the proposed revision of the rules governing variations to marketing authorisations, submitted to take into account new data, for example on efficacy or a new adverse effect ➡ https://tinyurl.com/4xuwmhh6?action=PIRSJUL

Zanubrutinib has been authorised for use in chronic lymphocytic leukaemia and Waldenström macroglobulinaemia (as has ibr...
23/07/2024

Zanubrutinib has been authorised for use in chronic lymphocytic leukaemia and Waldenström macroglobulinaemia (as has ibrutinib), and in certain patients with relapsed or refractory marginal zone lymphoma. Does zanubrutinib extend survival compared with the other options used in these situations, in particular ibrutinib? Does it have fewer or less severe adverse effects than ibrutinib? ➡ https://vu.fr/GYQNn?action=PIRSJUL

Methadone, a long-acting opioid, is used for the treatment of opioid dependence and as an analgesic. A French regional p...
19/07/2024

Methadone, a long-acting opioid, is used for the treatment of opioid dependence and as an analgesic. A French regional pharmacovigilance centre analysed, over a 10-year period, 509 reports of adverse effects in patients exposed to methadone, of which 8 out of 10 were serious. By being aware of the situations in which the use of methadone carries a risk of serious adverse effects, these situations can be anticipated ➡ https://vu.fr/leQP?action=PIRSJUL

Receive the free, monthly Newsletter from the editors of Prescrire International, a critical eye on new drugs authorised...
16/07/2024

Receive the free, monthly Newsletter from the editors of Prescrire International, a critical eye on new drugs authorised in Europe. Sign up here ➡ https://bit.ly/3uh2TBL?action=PIRSJUL

French appeal court finds Servier guilty of four charges, handing down sentences more respectful of the victims of decad...
10/07/2024

French appeal court finds Servier guilty of four charges, handing down sentences more respectful of the victims of decades of constant, organised deception ➡ https://vu.fr/blKwE?action=PIRSJUL

Nutri-Score is a labelling system for food and beverages that informs consumers about the product's nutritional quality....
08/07/2024

Nutri-Score is a labelling system for food and beverages that informs consumers about the product's nutritional quality. The label is displayed on food packaging on a voluntary basis by manufacturers, and by supermarket chains on their own-brand products ➡ https://vu.fr/htMMm?action=PIRSJUL

Dupilumab, an immunosuppressive monoclonal antibody directed against interleukin-4 and interleukin-13 receptors, has bee...
05/07/2024

Dupilumab, an immunosuppressive monoclonal antibody directed against interleukin-4 and interleukin-13 receptors, has been authorised in the European Union for the treatment of prurigo nodularis, a condition that can greatly impair patients' quality of life ➡ https://vu.fr/lVPxn?action=PIRSJUL

🔎 In the July/August issue of Prescrire International:- Dupilumab in prurigo nodularis- Methadone: an analysis of advers...
03/07/2024

🔎 In the July/August issue of Prescrire International:
- Dupilumab in prurigo nodularis
- Methadone: an analysis of adverse effects
- Mediator°: the appeal trial
This month's contents ➡ https://vu.fr/ajWB?action=PIRSJUL

Subscribe to Prescrire International, a critical eye on new drugs authorised in Europe https://bit.ly/3pZuBRt
28/06/2024

Subscribe to Prescrire International, a critical eye on new drugs authorised in Europe https://bit.ly/3pZuBRt

Association Mieux Prescrire, the legal entity that publishes Prescrire's journals and continuing education programmes, m...
24/06/2024

Association Mieux Prescrire, the legal entity that publishes Prescrire's journals and continuing education programmes, makes its accounts public every year. The summary of its 2023 annual financial report is publicly available here ➡ https://vu.fr/pYtKa?action=C4RSA

In a placebo-controlled trial in patients at high risk for cardiovascular events, their incidence was 1.5 percentage poi...
20/06/2024

In a placebo-controlled trial in patients at high risk for cardiovascular events, their incidence was 1.5 percentage points lower in the injectable semaglutide group than in the placebo group, with no reduction in mortality and at a cost of frequent, and often troublesome, adverse effects ➡ https://vu.fr/QXeTs?action=C4RSJ

In 2023, epidemiological data suggesting an increased incidence of neurodevelopmental disorders in children whose father...
17/06/2024

In 2023, epidemiological data suggesting an increased incidence of neurodevelopmental disorders in children whose father had taken a valproate drug during the 3 months prior to conception led several drug regulatory agencies to issue alerts about this potential risk. As of early 2024, what are the main evaluation data concerning this risk, how strong is the evidence they provide, and to what extent should they be taken into account in clinical practice? ➡ https://vu.fr/srmVe?action=C4RSJ

Receive the free, monthly Newsletter from the editors of Prescrire International, a critical eye on new drugs authorised...
13/06/2024

Receive the free, monthly Newsletter from the editors of Prescrire International, a critical eye on new drugs authorised in Europe. Sign up here ➡ https://bit.ly/3uh2TBL

Ever since Prescrire was launched in 1981, it has been criticised for its method of analysis, editorial process and cert...
10/06/2024

Ever since Prescrire was launched in 1981, it has been criticised for its method of analysis, editorial process and certain editorial choices. This article addresses a few of the recurring criticisms levelled against Prescrire ➡ https://vu.fr/FlRTm?action=C4RSJ

Each drug has its own story. Some are fine tales of discovery: the discovery of a rare or not so rare disease, its serio...
07/06/2024

Each drug has its own story. Some are fine tales of discovery: the discovery of a rare or not so rare disease, its serious or not so serious consequences, its natural course and causes, and then an effective treatment. In the best stories, the treatment benefits numerous patients for a very long time, its risks are considered acceptable, and the price society pays for it is fair ➡ https://vu.fr/ifWrf?action=C4RSJ

Faricimab is a monoclonal antibody that simultaneously targets 2 proteins involved in angiogenesis: vascular endothelial...
05/06/2024

Faricimab is a monoclonal antibody that simultaneously targets 2 proteins involved in angiogenesis: vascular endothelial growth factor (VEGF) and angiopoietin-2. It has been authorised in the European Union for intravitreal use in adults with neovascular (wet) age-related macular degeneration and in adults with loss of visual acuity due to diabetic macular oedema. What advantages does faricimab offer over VEGF inhibitors in these clinical situations? And what are its adverse effects? ➡ https://vu.fr/naArN?action=C4RSJ

🔎 In the June issue of Prescrire International:- Faricimab in age-related macular degeneration - Paternal exposure to va...
03/06/2024

🔎 In the June issue of Prescrire International:
- Faricimab in age-related macular degeneration
- Paternal exposure to valproate drugs: neurodevelopmental disorders in children?
- Recurring criticisms of Prescrire: how do we answer?
This month's contents ➡ https://vu.fr/ajWB?action=PIRSJU

Bisphenol A and titanium dioxide: the European Medicines Agency (EMA) disputes the need to remove these substances from ...
23/05/2024

Bisphenol A and titanium dioxide: the European Medicines Agency (EMA) disputes the need to remove these substances from health products, yet it is acknowledged that their presence in food is harmful ➡ https://vu.fr/GSWpO?action=PIRSMY

Efgartigimod alfa, an antibody Fc fragment that is claimed to increase IgG degradation by blocking the neonatal Fc recep...
20/05/2024

Efgartigimod alfa, an antibody Fc fragment that is claimed to increase IgG degradation by blocking the neonatal Fc receptor, has been authorised in the European Union as an add-on treatment in adults with generalised myasthenia gravis who have autoantibodies directed against acetylcholine receptors. Is efgartigimod alfa more effective at alleviating the symptoms of the disease than the other treatments proposed in this situation, does it prevent the complications of the disease, including myasthenic crisis, and what are its adverse effects? ➡ https://vu.fr/fqDg?action=PIRSMY

Address


Telephone

+33149237280

Website

Alerts

Be the first to know and let us send you an email when Prescrire International posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Prescrire International:

Videos

Discover the newly redesigned Prescrire International Subscribe here: https://bit.ly/3pZuBRt

Discover the newly redesigned Prescrire International ➡ Subscribe here: https://bit.ly/3pZuBRt

Discover the newly redesigned Prescrire International Subscribe here: https://bit.ly/3pZuBRt

Discover the newly redesigned Prescrire International! Subscribe here : https://bit.ly/3pZuBRt

Shortcuts

  • Address
  • Telephone
  • Alerts
  • Contact The Business
  • Videos
  • Claim ownership or report listing

  • Want your business to be the top-listed Media Company?

Share

A non-profit medical journal for better patient care

Reliable, rigorously independent information to enable fully informed decision-making. Prescrire International publishes 11 issues per year, with up-to-date reviews of new drugs, adverse effects and health policy issues, translated from acclaimed French medical journal La r***e Prescrire. Prescrire is financed by its subscribers. No grants, no advertising. No shareholders, no sponsors.

Learn more at english.prescrire.org

Terms of use The information publicly available online is of a general nature. It in no way reduces the need for patients to seek personalised medical attention from the healthcare system. Prescrire does not respond to any personal requests for information.